Home / Stocks / Sms Pharmaceuticals Ltd.
SMSPHARMA

Sms Pharmaceuticals Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹481.35

Change

+4.55 (0.95%)

Open

₹477.0

Prev. Close

₹476.8

Day High

₹484.0

Day Low

₹467.35

Volume Analysis

Traded

176,596

Delivered

77,017

Delivery %

43.61%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Promoter holding is rising
  • •Strong operating margin (20.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year revenue growth (19.3%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹504.44 ₹494.22 ₹487.79 ₹477.57 ₹471.14 ₹460.92 ₹454.49
Fibonacci ₹494.22 ₹487.86 ₹483.93 ₹477.57 ₹471.21 ₹467.28 ₹460.92
Camarilla ₹485.93 ₹484.4 ₹482.88 ₹477.57 ₹479.82 ₹478.3 ₹476.77

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+53.57%

1 Week

-8.11%

1 Month

+10.85%

3 Months

+34.98%

6 Months

+26.19%

1 Year

+69.55%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹148.5

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

12.79%

Net margin 12.05% × asset turnover 0.61x × equity multiplier 1.74x

Company Overview

Sector

Healthcare

Market Cap

₹4,758 Cr

P/E (TTM)

40.7

ROE

14.3%

Book Value

₹90.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Sms Pharmaceuticals Ltd. lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 59/100. The strongest factor is Financial Strength (94/100), while Cash Flow (13/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (20.0%). Strong 3-year revenue growth (19.3%).

TopFund Score — Fundamentals Quality

59/100 — Average

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

94

Growth

61

Valuation

20

Cash Flow

13

Corporate Governance

73

Momentum

90

Institutional Ownership

41

Business Quality

70

Risk & Volatility

64

Liquidity

44

From Screener.in

  • −Stock is trading at 5.65 times its book value
  • −Company has a low return on equity of 12.3% over last 3 years.
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Audio recording of 5 November 2026 investors call on Q2 and half-year results available online.

Newspaper cutting of published financial results

SMS Pharma reported Q2FY27 revenue up 30% to ₹316.08 crore; PAT rose 57%, and capex remains on track.

Investor Presentation for quarter and half year ended September 30, 2026

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 167 161 246 164 197 173 248 196 242 210 238 207 316
Expenses + 139 132 212 131 165 140 207 157 194 167 198 166 248
Operating Profit 28 29 34 34 31 33 41 39 48 44 40 41 68
OPM % 17.0% 18.0% 14.0% 20.0% 16.0% 19.0% 16.0% 20.0% 20.0% 21.0% 17.0% 20.0% 21.0%
Other Income + 1 1 2 1 1 2 1 1 1 4 3 2 1
Interest 6 6 6 5 5 4 5 6 6 6 5 6 6
Depreciation 8 8 8 8 9 9 9 10 10 10 10 10 10
Profit before tax 15 17 22 22 20 22 29 24 34 31 27 27 53
Tax % 21.0% 26.0% 26.0% 25.0% 29.0% 24.0% 30.0% 23.0% 26.0% 26.0% 23.0% 26.0% 25.0%
Net Profit + 12 11 17 16 14 18 20 20 25 23 33 21 40
EPS in Rs 1 1 2 2 2 2 2 2 3 3 3 2 4
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 5 9 64 22 18 7 1 19 23 21 -4 6 30

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2007 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 193 611 438 463 465 412 563 520 522 709 783 887 971
Expenses + 145 522 363 369 375 332 442 405 467 593 644 715 779
Operating Profit 47 89 75 93 90 80 121 115 55 117 139 172 192
OPM % 25.0% 15.0% 17.0% 20.0% 19.0% 19.0% 22.0% 22.0% 10.0% 16.0% 18.0% 19.0% 20.0%
Other Income + 5 4 1 2 3 5 3 5 5 4 6 8 9
Interest 8 17 16 15 12 12 11 19 22 24 19 23 23
Depreciation 5 19 19 20 19 22 22 32 32 32 34 40 41
Profit before tax 40 56 42 60 62 51 91 68 5 66 92 117 138
Tax % 36.0% 26.0% 14.0% 33.0% 34.0% 36.0% 33.0% 1.0% 28.0% 26.0% 27.0% 25.0% —
Net Profit + 25 41 28 32 40 32 63 62 -7 50 69 102 117
EPS in Rs 3 5 3 4 5 4 7 7 -1 6 8 11 12
Dividend Payout % 8.0% 4.0% 6.0% 7.0% 5.0% 7.0% 4.0% 4.0% -36.0% 7.0% 5.0% 4.0% —
Sales growth — — -28 6 0 -11 37 -8 0 36 10 13 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2007 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 182 285 246 276 313 340 402 462 452 528 631 776 833
Borrowings + 73 204 149 146 144 157 255 263 254 281 311 365 349
Other Liabilities + 64 158 89 72 93 103 147 126 165 217 202 212 268
Total Liabilities 329 656 493 503 559 608 812 860 880 1,034 1,153 1,362 1,461
Fixed Assets + 69 370 290 279 281 280 457 438 412 437 533 534 582
CWIP 15 13 8 8 18 42 7 11 33 30 35 122 138
Investments 0 21 29 28 27 26 27 22 11 11 12 26 28
Other Assets + 245 252 166 187 232 259 321 389 424 556 573 681 712
Total Assets 329 656 493 503 559 608 812 860 880 1,034 1,153 1,362 1,461
Equity Capital 10 8 8 8 8 8 8 8 8 8 9 9 9

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2007 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 14 61 73 32 50 40 90 45 22 50 82 59
Cash from Investing Activity + -32 -97 -39 -17 -35 -43 -152 -27 -30 -52 -123 -131
Cash from Financing Activity + 107 27 -33 -15 -13 -2 92 -12 -32 31 47 76
Net Cash Flow 89 -9 1 0 2 -5 31 6 -39 29 5 4
Free Cash Flow -5 -27 50 23 15 -3 -61 18 -7 -2 -42 -71
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 42 93 110 46 70 65 88 52 50 56 73 49

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 64.32% → 68.07%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 35.1% 33.18% 33.03% 32.27% 32.47% 31.23% 30.68% 28.77% 28.69% 28.6% 28.45% 30.55%
Promoters 64.32% 64.67% 64.67% 64.67% 64.67% 66.27% 66.27% 68.07% 68.07% 68.07% 68.07% 68.07%
FII 0.59% 0.17% 0.18% 0.52% 0.31% 0.08% 0.03% 0.28% 0.04% 0.31% 0.65% 1.18%
DII 0.0% 1.98% 2.13% 2.55% 2.55% 2.43% 3.03% 2.88% 3.21% 3.02% 2.83% 0.19%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sms Pharmaceuticals Ltd. (this stock) 4,758 40.7 5.64 14.3%
Gujarat Themis Biosyn Ltd 4,659 239.0 4.55 16.2%
Aarti Drugs Ltd. 4,589 19.9 2.73 13.4%
Zota Health Care Limited 4,492 — 7.17 -15.0%
Morepen Lab. Ltd 5,061 26.8 3.67 5.33%
Gufic Biosciences Ltd. 4,415 55.1 6.21 10.1%
Kwality Pharmaceuticals L 4,370 45.3 11.31 22.6%

Which Mutual Funds Hold Sms Pharmaceuticals Ltd.?

Frequently Asked Questions about Sms Pharmaceuticals Ltd.

Community Sentiment

What are other investors saying about Sms Pharmaceuticals Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.